These findings highlighted that OSU-2S, devoid of S1P1 receptor modulating activity, is a novel PKCδ-targeted antitumor agent via ROS generation and has clinical value in therapeutic strategies for HCC. Here, PRKCD is linked to hepatocellular carcinoma.